MedTrace Logo

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

NCT03285672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2018-11-01

No results posted yet for this study

Summary

The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.

Conditions

Interventions

DRUG

FP-101

Dose 1

DRUG

Placebo Comparator

Dose 1

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Fervent Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • George Raad · PMG Research of Charlotte, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2018-10-29
Completion
2018-10-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03285672 on ClinicalTrials.gov